Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis.

[1]  Kyoung-Sik Cho,et al.  Region-based diagnostic performance of multidetector CT for detecting peritoneal seeding in ovarian cancer patients , 2011, Archives of Gynecology and Obstetrics.

[2]  B. Rimel,et al.  The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. , 2010, Gynecologic oncology.

[3]  Douglas G Altman,et al.  Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study , 2010, BMJ : British Medical Journal.

[4]  Priyanka Prakash,et al.  Role of PET/CT in ovarian cancer. , 2010, AJR. American journal of roentgenology.

[5]  Jae Hoon Kim,et al.  Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. , 2010, Gynecologic oncology.

[6]  K. Sugimura,et al.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  K. Sugimura,et al.  Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Byung Kwan Park,et al.  Detection of Recurrent Ovarian Cancer at MRI: Comparison With Integrated PET/CT , 2007, Journal of computer assisted tomography.

[9]  J. Magrina,et al.  Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. , 2007, Gynecologic oncology.

[10]  V. Bettinardi,et al.  Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  N. Avril,et al.  Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. , 2007, Gynecologic oncology.

[12]  A. Coomarasamy,et al.  Meta-DiSc: a software for meta-analysis of test accuracy data , 2006, BMC medical research methodology.

[13]  E. Hauth,et al.  Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. , 2005, European journal of radiology.

[14]  R. Wahl,et al.  Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. , 2005, Gynecologic oncology.

[15]  B. Duggan,et al.  Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. , 2005, Radiology.

[16]  T. Miyamoto,et al.  Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[17]  F. Fazio,et al.  Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. , 2004, Radiology.

[18]  R. Wahl,et al.  PET-CT detection of abdominal recurrence of ovarian cancer: radiologic–surgical correlation , 2004, Abdominal Imaging.

[19]  A. Kuten,et al.  Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  L. Mortelmans,et al.  Positron Emission Tomography with FDG in the Detection of Peritoneal and Retroperitoneal Metastases of Ovarian Cancer , 2003, Gynecologic and Obstetric Investigation.

[21]  R. Felix,et al.  Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer , 2003, European Radiology.

[22]  Lale Kostakoglu,et al.  Clinical role of FDG PET in evaluation of cancer patients. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[24]  E. Fishman,et al.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography , 2000, Cancer.

[25]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  B J McNeil,et al.  Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. , 2000, Radiology.

[27]  Michael N. Maisey,et al.  Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine , 1999, European Journal of Nuclear Medicine.

[28]  F. Parazzini,et al.  Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. , 1999, Gynecologic oncology.

[29]  H. Hricak,et al.  Ovarian cancer: staging with CT and MR imaging. , 1995, Radiology.

[30]  R. Zepp,et al.  Ovarian carcinoma: value of CT in predicting success of debulking surgery. , 1995, AJR. American journal of roentgenology.

[31]  H. Hricak,et al.  Ovarian cancer recurrence: value of MR imaging. , 1995, Radiology.

[32]  N. Rofsky,et al.  Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. , 2010, Radiology.

[33]  Y. Yonekura,et al.  Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. , 2004, AJR. American journal of roentgenology.

[34]  Lisa A. Weissfeld,et al.  An assessment of the use of the continuity correction for sparse data in meta-analysis , 1996 .

[35]  G. Grégoire,et al.  Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? , 1995, Journal of clinical epidemiology.